Due to small size of Myomedin binders, which allows an increased tumor tissue penetration, the engineered MBA protein variants should be beneficial for monitoring PD-1+ cell populations in solid tumors, including NSCLC. The gene discussed is PDCD1; the disease is neoplasm.